Skip to main content

Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International PLC is a British biopharmaceutical enterprise specializing in the discovery, acquisition, clinical development, and commercialization of innovative therapeutic medicines for patients suffering from debilitating autoinflammatory and cardiovascular diseases, prominently featuring commercialized products such as Arcalyst (rilonacept) approved for recurrent pericarditis and mavrilimumab evaluated in severe autoimmune conditions. The company conducts advanced clinical research in immunology and biopharmaceuticals. Its core business operations encompass clinical-stage drug development, biopharmaceutical commercialization, immunology research, and medical affairs management. Revenue is derived primarily from direct commercial product sales of Arcalyst across the United States. Kiniksa Pharmaceuticals International holds a leading market position in autoinflammatory therapeutics and recurrent pericarditis treatment. The company is headquartered in Hamilton, Bermuda, with operational headquarters in Braintree, Massachusetts, United States, and its Class A ordinary shares trade on the Nasdaq Global Select Market under the ticker KNSA.

5 of the funds FundTelligence covers report a position in Kiniksa Pharmaceuticals International.

Legal name
Kiniksa Pharmaceuticals International PLC
Sector
Health Care
Country
United Kingdom
Funds holding it
5

Funds holding Kiniksa Pharmaceuticals International

Loading...